Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 22
- 试验地点
- 59
- 主要终点
- Progression Free Survival
研究概览
简要总结
This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer.
详细描述
This study is a randomized, double-blind, placebo-controlled international phase 2 trial in patients with HRG+, HR+, HER2- metastatic breast cancer that has progressed following treatment with no more than 2 prior therapies, one of which must have been a CDK inhibitor. All patients will be screened for heregulin using central testing, and eligible patients will be randomized to receive either seribantumab + fulvestrant or placebo + fulvestrant. Disease status will be assessed according to RECIST v 1.1 to support the primary endpoint.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 Study.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •To be eligible for participation in the study, patients must meet the following criteria. Patients who are HRG negative do not need to complete screening procedures beyond HRG assessment.
- •Patients must have histologically or cytologically confirmed ER+ and/or PR+ (with staining of >1% cells) breast cancer.
- •Patients with confirmed postmenopausal status due to either surgical/natural menopause or ovarian suppression.
- •Patients must be HER2 negative.
- •Patient must have at least one lesion amenable to either core needle biopsy or fine needle aspiration.
- •Patient must have a positive in-situ hybridization (ISH) test for heregulin, as determined by centralized testing of unstained tumor tissue.
- •Patients that have progressed following at least one but no more than two prior systemic therapies in the locally advanced or metastatic disease setting.
- •Patients with documented progression of locally advanced or metastatic disease as defined by RECISTv1.1 (Exception: patients with bone-only metastatic disease are eligible if they have at least 2 lytic lesions visible on a CT or MRI and have documented disease progression on prior therapy based on the appearance of new lesions).
- •Patients with bone-only lesions who have received radiation to those lesions must have documented progression following radiation therapy.
- •ECOG Performance Score (PS) of 0 or
- •Patients with adequate bone marrow reserves.
- •Adequate hepatic function.
- •Adequate renal function.
- •Patient has recovered from clinically significant effects of any prior, surgery, radiosurgery, or other antineoplastic therapy.
- •Patients who have experienced a venous thromboembolic event within 60 days of signing the main consent form should have been treated with anti-coagulants for at least 7 days prior to beginning treatment and for the duration of treatment on this study.
排除标准
- •Patients must meet all the inclusion criteria listed above and none of the following exclusion criteria.
- •Prior treatment with an anti-ErbB3 antibody.
- •Prior treatment with a chemotherapy in the locally advanced or metastatic disease setting.
- •Patients cannot have received prior treatment with fulvestrant or other SERDs in the locally advanced or metastatic setting.
- •Uncontrolled CNS disease or presence of leptomeningeal disease.
- •Inflammatory breast cancer.
- •History of another active malignancy that required systemic therapy in the last 2 years. Patients with prior history of in-situ cancer, basal, or squamous cell skin cancer are eligible.
- •Patients with an active infection, or unexplained fever > 38.5 C during screening visits or on the first scheduled day of dosing, which in the investigator's opinion might compromise the patients participation in the trial or affect the study outcome. At the discretion of the investigator, patients with tumor fever may be enrolled.
- •Known hypersensitivity to any of the components of seribantumab, fulvestrant, or who have had hypersensitivity reactions to fully human monoclonal antibodies.
- •NYHA Class III or IV congestive heart failure.
- •Patients with a significant history of cardiac disease (i.e. uncontrolled blood pressure, unstable angina, myocardial infarction within 1 year or ventricular arrhythmias requiring medication) are also excluded.
- •Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; or active human immunodeficiency virus (HIV) infection, active hepatitis B infection or active hepatitis C infection.
研究组 & 干预措施
Arm A
Seribantumab
Fulvestrant
干预措施: Seribantumab (Drug)
Arm A
Seribantumab
Fulvestrant
干预措施: Fulvestrant (Drug)
Arm B
Placebo
Fulvestrant
干预措施: Fulvestrant (Drug)
Arm B
Placebo
Fulvestrant
干预措施: Placebo (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: Randomization until progression of disease or death due to any cause up to 13 months (The study terminated prematurely) . The primary analysis was planned to be initiated when 58 PFS events have occurred
Progression Free Survival is defined as the time from randomization to the first documented radiographical progression of disease using RECIST v1.1 or death from any cause, whichever comes first as assessed by the investigator. The tumor assessment (i.e., scan dates) was used for progression/censor date not the date corresponding to the determination of overall response. Progression-free survival time distribution and median survival for each treatment group were analyzed using the Kaplan-Meier method.
次要结局
- Number of Participants With Treatment-emergent Adverse Events Reported With the Combinations of Seribantumab Plus Fulvestrant Versus Fulvestrant Alone(TEAEs were collected through the study completion (30 Nov 2018), up to 13 months. Frequency and percent summaries were presented for TEAE defined as adverse events that occur or worsen in severity following the first dose of seribantumab, or fulvestrant)
- Percentage of Treatment-emergent Adverse Events Reported With the Combinations of Seribantumab Plus Fulvestrant Versus Fulvestrant Alone(TEAEs were collected through the study completion (30 Nov 2018), up to 13 months. Frequency and percent summaries were presented for TEAE defined as adverse events that occur or worsen in severity following the first dose of seribantumab, or fulvestrant)
- Time to Progression(Randomization to date of objective tumor progression up to 13 months (The study terminated prematurely))
- Overall Survival(Randomization until death due to any cause up to 13 months (The study terminated prematurely))
- Objective Response Rate(Randomization through end of study up to 13 months (The study terminated prematurely))
- Pharmacokinetic (PK) Profile of Seribantumab When Given in Combination With Fulvestrant and of Fulvestrant When Given in Combination With Serbantumab.(The study terminated prematurely after 13 months. Were to be analyzed post-dose on Cycle 1,Week 1 & pre-dose for all subsequent seribantumab infusions until the completion of Cycle 2. Fulvestrant PK samples were to be collected prior to seribantumab dose)